A5100643690- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- Gastric Cancer Management and Outcomes
- Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Multiple Myeloma Research and Treatments
- Radiomics and Machine Learning in Medical Imaging
- T-cell and Retrovirus Studies
- Monoclonal and Polyclonal Antibodies Research
- Cutaneous lymphoproliferative disorders research
- Immune Cell Function and Interaction
- Breast Cancer Treatment Studies
- Ubiquitin and proteasome pathways
- Advanced Breast Cancer Therapies
- PI3K/AKT/mTOR signaling in cancer
- Biosimilars and Bioanalytical Methods
- Bone Tumor Diagnosis and Treatments
- Head and Neck Cancer Studies
- Glycosylation and Glycoproteins Research
- Clusterin in disease pathology
- Cardiac Health and Mental Health
- Pancreatic and Hepatic Oncology Research
- Cardiac tumors and thrombi
Fujian Provincial Cancer Hospital
2018-2025
Yichang Central People's Hospital
2025
China Three Gorges University
2025
Zhejiang Shuren University
2025
Fujian Medical University
2018-2024
Regend Therapeutics (China)
2024
China Pharmaceutical University
2024
Dalian Municipal Central Hospital
2024
Dalian University of Technology
2024
Cancer Hospital of Chinese Academy of Medical Sciences
2021
Relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) is a rare and aggressive type of non-Hodgkin with limited treatment options. This phase II study evaluated the efficacy safety sugemalimab, an anti-PD-L1 monoclonal antibody, in R/R ENKTL.Eligible patients received sugemalimab 1,200 mg intravenously once every 3 weeks for up to 24 months until progression, death, withdrawal. The primary end point was objective response rate (ORR) assessed by independent radiologic...
Abstract Extranodal natural killer/T‐cell lymphoma, nasal‐type (ENKTL) is a distinct subtype of non‐Hodgkin lymphoma and most the patients presented localized disease. Combined modality therapy (CMT), namely chemotherapy combined with radiotherapy, has been recommended for early‐stage ENKTL. However, optimal CMT not fully clarified. This study reports efficacy toxicity sequential P‐GEMOX (pegaspargase, gemcitabine oxaliplatin) radiotherapy in large Chinese cohort comprising 202 diagnosed...
Subcutaneous (SC) rituximab has demonstrated advantages over intravenous (IV) administration; however, insufficient data exist on its use with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in Chinese patients diffuse large B-cell lymphoma (DLBCL). This multicenter, phase II, randomized, controlled study was conducted across China between February 2021 October 2022. Fifty adult previously untreated CD20-positive DLBCL were randomized to receive one cycle of IV seven...
This registration study assessed clinical outcomes of TQ-B3525, the dual phosphatidylinositol-3-kinase (PI3K) α/δ inhibitor, in relapsed and/or refractory follicular lymphoma (R/R FL). phase II (ClinicalTrials.gov NCT04324879. Registered March 27, 2020) comprised run-in stage and 2. R/R FL patients after ≥2 lines therapies received oral 20 mg TQ-B3525 once daily a 28-day cycle until intolerable toxicity or disease progression. Primary endpoint was independent review committee (IRC)-assessed...
Chidamide has demonstrated significant clinical benefits for patients with relapsed/refractory (R/R) PTCL in previous studies. This multi-center observational study was aimed to evaluate the objective response rate (ORR), overall survival (OS), and safety of chidamide. From February 2015 December 2017, 548 R/R from 186 research centers China were included study. Among 261 treated chidamide monotherapy, ORR 58.6% 55 (21.1%) achieved complete (CR). 287 receiving chidamide-containing...
Abstract HLX01 (HanliKang ® ) is a rituximab biosimilar that showed bioequivalence to reference in untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) the phase 3 HLX01-NHL03 study. Here, we report 5-year follow-up results from open-label extension part. Patients were randomised either plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or CHOP (H-CHOP) every 21 days for up six cycles. The primary efficacy endpoint was overall survival (OS), secondary...
Depression ranks as the fourth most prevalent global disease, with suicide incidents occurring at a younger age. Sulpiride (SUL), an atypical antidepressant drug acting dopamine D2 receptor antagonist and possessing anti-inflammatory properties, exhibits limited ability to penetrate blood brain barrier (BBB). This weak penetration hampers its inhibitory effect on prolactin release in pituitary gland, consequently leading hyperprolactinemia. In order enhance central nervous system efficacy of...
Abstract Background While the epidemiologic association between hepatitis B virus (HBV) infection and diffuse large B-cell lymphoma (DLBCL) is established, little known about pathological characteristics outcome of DLBCL arising in patients with HBV infection. Methods We retrospectively studied a cohort 420 for incidence infection, clinicopathologic features prognostic factors HBsAg-positive China, endemic area. Results In our study, 127 (30.2%) were HBsAg-positive. displayed younger median...
This study aimed to investigate the latent Epstein-Barr virus (EBV) infection status of patients with newly diagnosed Hodgkin lymphoma (HL) and discuss relationship between tumor cell EBV prognosis HL patients.A total 134 previously untreated were analyzed in study. encoded RNAs (EBERs) situ hybridization was performed detect cells.EBV positive correlated sex (p=0.046) proportion extranodal lesions(p=0.037). There no obvious correlation overall survival (OS) or failure-free (FFS) all cases,...
7057 Background: TQ-B3525 is a novel and selective oral PI3K α/δ inhibitor. In an earlier Phase I trial, achieved outstanding efficacy in subjects with refractory/relapsed follicular lymphoma (R/R FL) (2020 ASCO Abstract #8058). Here, we report the result from single-arm, open-label, phase II registration study evaluating safety of R/R FL patients. Methods: This included exploratory stage 1 confirmatory 2. Patients after ≥2 lines therapies received 20 mg once daily 28-day cycle until disease...
To analyze the clinicopathological features and prognostic factors of patients with diffuse large B-cell lymphoma(DLBCL).Ninety-four cases DLBCL followed up were selected in Fujian Tumor Hospital. The immunohistochemistry method was used to detect protein expressions BCL-2 BCL-6, MYC, CD10 MUM-1, gene abnormalities MYC analyzed by fluorescence situ hybridization, clinical pathological related affecting prognosis analyzed.The positive rates BCL-2, MUM-1 94 75.53% (71/94), 58.51% (55/94),...